We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.

Submit a Manuscript to the Journal

Annals of Medicine

For an Article Collection on

Present and Future Therapeutic Opportunities for the Treatment of Cardiometabolic Disorders: Focus on Dyslipidemia and Atherosclerosis

Manuscript deadline
31 July 2023

Cover image - Annals of Medicine

Article collection guest advisor(s)

Giuseppe Danilo Norata, University of Milan, Milan, Italy
[email protected]

Andrea Baragetti, University of Milan, Milan, Italy
[email protected]

Fabrizia Bonacina, University of Milan, Milan, Italy
[email protected]

Submit an ArticleVisit JournalArticles

Present and Future Therapeutic Opportunities for the Treatment of Cardiometabolic Disorders: Focus on Dyslipidemia and Atherosclerosis

Atherosclerosis is recognized as one of the most important pathologies leading to acute cardiovascular events, and it is still one of the principal causes of morbidity and mortality worldwide. Elevated plasma cholesterol levels and apolipoprotein B-containing particles are causally associated with atherosclerosis development and cardiovascular disease (CVD) morbidity and mortality. Although a combination of cause-lowering therapies contributes to reducing cardiovascular morbidity and mortality, patients with low LDL-C still present a residual CVD risk.

In recent years, pharmacological research has guided the development of ground-breaking techniques. For instance, anti-PCSK9 monoclonal antibodies not only display potent cholesterol-lowering effects but also exert anti-atherosclerotic potential, even in very high-risk patients previously untreatable with classical therapies. However, many patients still experience a residual CVD risk, driven by additional pathological mechanisms of atherosclerosis, including other classes of lipoproteins, such as TG-rich lipoproteins and Lp(a), as well as immune-inflammatory players or gluco-metabolic mediators.

Further pharmacological advancements are needed to optimize the therapeutic chances for all patients who cannot be effectively treated with classical cholesterol-lowering drugs. Identifying alternative viable strategies to lessen the magnitude of exposure to CVD risk factors will help to minimize the occurrence of acute events and reduce the spread of CVD.

New biomarkers and therapeutic targets are promising. Among them, novel lipoprotein targets (genetically increased levels of Lp(a) or high levels of triglyceride-rich lipoproteins), impaired immune-inflammatory response and thrombosis, systemic gluco-metabolic players of ectopic visceral adiposity, as well as indicators of adverse environmental exposures (intestinal dysbiosis or epigenetic modifiers).

This Article Collection aims to solicit state-of-the-art reviews and original basic and clinical research, including but not limited to current therapeutic strategies, those under clinical advancement, and emerging targets that might affect the development of atherosclerosis and reduce CVD.

Annals of Medicine accepts the following types of articles:

  • Research Article
  • Clinical Study
  • Study Characteristics
  • Systematic Review
  • Review Article
  • Mini Review
  • Case Series

When submitting your article, please select the section 'Pharmacology', and the Article Collection, 'Present and Future Therapeutic Opportunities for the Treatment of Cardiometabolic Disorders: Focus on Dyslipidemia and Atherosclerosis' from the drop-down menu on the submission system.

Benefits of publishing open access within Taylor & Francis

Global marketing and publicity, ensuring your research reaches the people you want it to.

Article Collections bring together the latest research on hot topics from influential researchers across the globe.

Rigorous peer review for every open access article.

Rapid online publication allowing you to share your work quickly.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.